Clinical Study

Efficacy And Safety Of A Treatment For Eczema (Atopic Dermatitis)

Posted Date: Sep 16, 2019

  • Investigator: Alan Fleischer
  • Specialties: Dermatology, Skin Disease
  • Type of Study: Drug

This is a placebo-controlled study in adult and adolescent participants with moderate to severe atopic dermatitis. The study drug is an antibody that blocks a receptor involved with atopic dermatitis development and itchiness. Eligible participants will be randomly distributed to the experimental (drug) or placebo group in a ratio (2:1). Eligible participants will receive subcutaneous injections for 16-weeks. At week 16 visit participants will be evaluated as responders or non-responders. The responders will continue to the maintenance period of the study. The non-responders may be eligible to enroll into a long-term extension study.


Eligible Subjects Must Have Documented History Of Atopic Dermatitis For At Least 2 Years; Easi Score >16; Iga>3; Bsa Involvement >10%; Failure To Achieve Or Maintain Disease Remission; Agree To Apply Moisturizer During The Duration Of The Study; Willing To Comply With All Procedures, Including Recording Daily Diary.


Dermatitis, Antibody, Itchiness

For More Information:

Jordan Perry

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.